CHBIO (6534) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 正瀚-創

CHBIO (6534) reported revenue of NT$62 million for Oct 2026, -26.4% year on year and -47.6% from the previous month. Revenue for Jan–Oct 2026 was NT$1.61 billion (+2.3% year on year).

In Oct 2026, it ranked No. 93 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$72 million24/10Nov 2024 NT$68.9 millionDec 2024 NT$134.6 millionJan 2025 NT$218.1 millionFeb 2025 NT$267.3 million25/02Mar 2025 NT$368.3 millionApr 2025 NT$219.6 millionMay 2025 NT$131.8 millionJun 2025 NT$69.1 million25/06Jul 2025 NT$50.7 millionAug 2025 NT$59.9 millionSep 2025 NT$106.1 millionOct 2025 NT$84.2 million25/10Nov 2025 NT$91.2 millionDec 2025 NT$153 millionJan 2026 NT$219.3 millionFeb 2026 NT$272.9 million26/02Mar 2026 NT$377.3 millionApr 2026 NT$229.2 millionMay 2026 NT$141.4 millionJun 2026 NT$88.9 million26/06Jul 2026 NT$62.2 millionAug 2026 NT$39.9 millionSep 2026 NT$118.3 millionOct 2026 NT$62 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$62 million-26.4%-47.6%
Sep 2026NT$118.3 million+11.5%+196.5%
Aug 2026NT$39.9 million-33.4%-35.9%
Jul 2026NT$62.2 million+22.7%-30.0%
Jun 2026NT$88.9 million+28.6%-37.1%
May 2026NT$141.4 million+7.3%-38.3%
Apr 2026NT$229.2 million+4.4%-39.3%
Mar 2026NT$377.3 million+2.5%+38.3%
Feb 2026NT$272.9 million+2.1%+24.4%
Jan 2026NT$219.3 million+0.6%+43.3%
Dec 2025NT$153 million+13.7%+67.8%
Nov 2025NT$91.2 million+32.4%+8.3%
Oct 2025NT$84.2 million+17.0%-20.6%
Sep 2025NT$106.1 million+94.7%+77.1%
Aug 2025NT$59.9 million+84.4%+18.1%
Jul 2025NT$50.7 million+6.0%-26.6%
Jun 2025NT$69.1 million+2.9%-47.6%
May 2025NT$131.8 million+3.2%-40.0%
Apr 2025NT$219.6 million+6.7%-40.4%
Mar 2025NT$368.3 million+4.4%+37.8%
Feb 2025NT$267.3 million+6.9%+22.6%
Jan 2025NT$218.1 million-1.8%+62.1%
Dec 2024NT$134.6 million+83.0%+95.4%
Nov 2024NT$68.9 million+31.1%-4.3%
Oct 2024NT$72 million+307.6%+32.1%

Jan–Oct 2026 cumulative: NT$1.61 billion (+2.3% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: CHBIO vs PEC / CHBIO vs Lotus Pharm / CHBIO vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16